📊 LNAI Key Takeaways
Is Lunai Bioworks Inc. (LNAI) a Good Investment?
Lunai Bioworks exhibits critical financial distress with negative stockholders' equity (-$13.5M), near-zero and collapsing revenue ($24.3K, -203.8% YoY), and negative operating cash flow (-$2.4M). The company cannot sustain operations or service $20.2M liabilities with current economics, presenting severe bankruptcy risk.
Fundamentals indicate acute financial distress: de minimis revenue with massive operating losses, negative equity, and a critical liquidity position (0.03x current ratio, ~$0.5M cash vs. -$2.4M OCF). Reported net income appears driven by non-operating/one-time items, masking weak core operations. Absent immediate financing and a credible path to sustainable revenue, dilution or restructuring risk dominates.
Why Buy Lunai Bioworks Inc. Stock? LNAI Key Strengths
- Minimal capital expenditure requirements reduce ongoing cash burn beyond operating losses
- Pharmaceutical sector positioning retains potential value if pipeline assets attract partnership or acquisition
- Small asset base could facilitate orderly restructuring or strategic transaction
- Asset-light model with minimal capex needs
- Low absolute long-term debt balance
- Recent net profit from non-operating items provides temporary cushion
LNAI Stock Risks: Lunai Bioworks Inc. Investment Risks
- Negative stockholders' equity of -$13.5M indicates technical insolvency
- Revenue collapse of 203.8% YoY with near-zero topline suggests complete operational failure
- Operating cash outflow of -$2.4M unsustainable; current cash of $491.6K provides only ~3 months runway
- Critically low liquidity (0.03x current ratio) with $20.2M total liabilities; inability to meet short-term obligations
- Negative interest coverage (-6.8x) indicates inability to service debt from operations; no Form 4 insider activity suggests management loss of confidence
- Severe liquidity shortfall and going-concern risk
- Negative shareholders’ equity and high dependence on external financing/dilution
- Collapsing revenue and deeply negative operating margins
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before insolvency
- Any revenue stabilization or partnership/licensing deal announcements
- Stockholders' equity trajectory and capital raise activity
- Changes in total liabilities indicating restructuring or debt repayment
- Cash runway (cash vs. quarterly operating cash burn)
- Current ratio and net working capital
Lunai Bioworks Inc. (LNAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
LNAI Profit Margin, ROE & Profitability Analysis
LNAI vs Healthcare Sector: How Lunai Bioworks Inc. Compares
How Lunai Bioworks Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lunai Bioworks Inc. Stock Overvalued? LNAI Valuation Analysis 2026
Based on fundamental analysis, Lunai Bioworks Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lunai Bioworks Inc. Balance Sheet: LNAI Debt, Cash & Liquidity
LNAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lunai Bioworks Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.91 indicates the company is currently unprofitable.
LNAI Revenue Growth, EPS Growth & YoY Performance
LNAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | N/A | $15.0K | N/A |
| Q3 2017 | $42.5K | -$207.6K | N/A |
| Q2 2017 | $42.5K | -$275.5K | N/A |
| Q3 2016 | $42.5K | -$207.6K | N/A |
| Q2 2016 | $42.5K | -$275.5K | N/A |
| Q3 2014 | $925 | -$371.5K | N/A |
| Q2 2014 | $31.6K | -$343.9K | N/A |
| Q1 2014 | $31.6K | -$399.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lunai Bioworks Inc. Dividends, Buybacks & Capital Allocation
LNAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lunai Bioworks Inc. (CIK: 0001527728)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNAI
What is the AI rating for LNAI?
Lunai Bioworks Inc. (LNAI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNAI's key strengths?
Claude: Minimal capital expenditure requirements reduce ongoing cash burn beyond operating losses. Pharmaceutical sector positioning retains potential value if pipeline assets attract partnership or acquisition. ChatGPT: Asset-light model with minimal capex needs. Low absolute long-term debt balance.
What are the risks of investing in LNAI?
Claude: Negative stockholders' equity of -$13.5M indicates technical insolvency. Revenue collapse of 203.8% YoY with near-zero topline suggests complete operational failure. ChatGPT: Severe liquidity shortfall and going-concern risk. Negative shareholders’ equity and high dependence on external financing/dilution.
What is LNAI's revenue and growth?
Lunai Bioworks Inc. reported revenue of $24.3K.
Does LNAI pay dividends?
Lunai Bioworks Inc. does not currently pay dividends.
Where can I find LNAI SEC filings?
Official SEC filings for Lunai Bioworks Inc. (CIK: 0001527728) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNAI's EPS?
Lunai Bioworks Inc. has a diluted EPS of $0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LNAI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lunai Bioworks Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LNAI stock overvalued or undervalued?
Valuation metrics for LNAI: ROE of N/A (sector avg: 15%), net margin of 4,193.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LNAI stock in 2026?
Our dual AI analysis gives Lunai Bioworks Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LNAI's free cash flow?
Lunai Bioworks Inc.'s operating cash flow is $-2.4M, with capital expenditures of $1.2K. FCF margin is -9,959.9%.
How does LNAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4,193.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).